Cell and gene therapies are being introduced into healthcare at an increasing rate. Developments in this field show great promise for curing previously untreatable diseases.
However, startups in the gene and cell therapy sector face greater hurdles than those developing therapies based on small molecules or biologics. The market is still emerging, and regulations, manufacturing infrastructure, and financing opportunities are constantly evolving.
Welcome to a seminar exploring how to overcome the key barriers in the field.
Experts from HOYA Consulting and AWA will share insights and lessons learned on navigating intellectual property protection, regulatory landscapes, funding challenges, and manufacturing complexities.
Take the opportunity to gain practical knowledge on structuring a successful cell and gene therapy venture while mitigating risks. Whether you're spinning out a company, supporting academic innovation, or investing in advanced therapies – this event is for you.
- Joanna Applequist, European Patent Attorney and Partner at AWA
- Edit Szodorai, Senior Associate at AWA
- Ajdin Jakupovic, Co-founder and Managing Partner at HOYA Consulting
- Heather Main, Principal and Co-founder at HOYA Consulting
When: Thursday, April 24. 8:30-9:45. Breakfast is served from 8:00.
Where: Kantinen, Forskaren, Hagaplan 4, Stockholm
Register on this link no later than April 17 >>
The seminar is being conducted as part of the Health Data Sweden (HDS) project, which works to support small and medium-sized enterprises and the public sector in digitalizing health data.
